All patients
Age < 65y (younger) Age > 65y Asian type ECOG ⩾ 1 ECOG 0 PD-L1 < 1% PD-L1 > 1%
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
studies
metastatic/advanced OC (mOC) - 2nd line (L2), avelumab alone vs. chemotherapy, meta-analysis of study results Outcome TE 95% CI n k I2 ROB Pub. bias deaths (OS)detailed results JAVELIN ovarian 200 (A vs doxorubicin), 2021 1.14 [0.88; 1.47]
1.14 [0.88 ; 1.47 ] JAVELIN ovarian 200 (A vs doxorubicin), 2021 1 0% 378 NA not evaluable progression or deaths (PFS)detailed results JAVELIN ovarian 200 (A vs doxorubicin), 2021 1.68 [1.20; 2.36]
1.68 [1.20 ; 2.36 ] JAVELIN ovarian 200 (A vs doxorubicin), 2021 1 0% 378 NA not evaluable DCRdetailed results JAVELIN ovarian 200 (A vs doxorubicin), 2021 2.02 [1.33; 3.07]
2.02 [1.33 ; 3.07 ] JAVELIN ovarian 200 (A vs doxorubicin), 2021 1 0% 378 NA not evaluable objective responses (ORR)detailed results JAVELIN ovarian 200 (A vs doxorubicin), 2021 0.89 [0.27; 2.92]
0.89 [0.27 ; 2.92 ] JAVELIN ovarian 200 (A vs doxorubicin), 2021 1 0% 378 NA not evaluable TRAE (any grade)detailed results JAVELIN ovarian 200 (A vs doxorubicin), 2021 0.45 [0.26; 0.76]
0.45 [0.26 ; 0.76 ] JAVELIN ovarian 200 (A vs doxorubicin), 2021 1 0% 364 NA not evaluable TRAE (grade 3-4)detailed results JAVELIN ovarian 200 (A vs doxorubicin), 2021 0.41 [0.24; 0.68]
0.41 [0.24 ; 0.68 ] JAVELIN ovarian 200 (A vs doxorubicin), 2021 1 0% 364 NA not evaluable TRAE leading to death (grade 5)detailed results JAVELIN ovarian 200 (A vs doxorubicin), 2021 0.95 [0.06; 15.24]
0.95 [0.06 ; 15.24 ] JAVELIN ovarian 200 (A vs doxorubicin), 2021 1 0% 364 NA not evaluable TRAE leading to discontinuation (any grade)detailed results JAVELIN ovarian 200 (A vs doxorubicin), 2021 0.87 [0.38; 1.95]
0.87 [0.38 ; 1.95 ] JAVELIN ovarian 200 (A vs doxorubicin), 2021 1 0% 364 NA not evaluable Abdominal pain TRAE (grade 3-4)detailed results JAVELIN ovarian 200 (A vs doxorubicin), 2021 0.47 [0.02; 14.15]
0.47 [0.02 ; 14.15 ] JAVELIN ovarian 200 (A vs doxorubicin), 2021 1 0% 364 NA not evaluable Acute kidney injury TRAE (grade 3-4)detailed results JAVELIN ovarian 200 (A vs doxorubicin), 2021 1.90 [0.06; 56.93]
1.90 [0.06 ; 56.93 ] JAVELIN ovarian 200 (A vs doxorubicin), 2021 1 0% 364 NA not evaluable Adrenal insufficiency TRAE (grade 3-4)detailed results JAVELIN ovarian 200 (A vs doxorubicin), 2021 0.95 [0.02; 47.96]
0.95 [0.02 ; 47.96 ] JAVELIN ovarian 200 (A vs doxorubicin), 2021 1 0% 364 NA not evaluable Anaemia TRAE (grade 3-4)detailed results JAVELIN ovarian 200 (A vs doxorubicin), 2021 0.30 [0.08; 1.14]
0.30 [0.08 ; 1.14 ] JAVELIN ovarian 200 (A vs doxorubicin), 2021 1 0% 364 NA not evaluable Asthenia TRAE (grade 3-4)detailed results JAVELIN ovarian 200 (A vs doxorubicin), 2021 0.47 [0.02; 14.15]
0.47 [0.02 ; 14.15 ] JAVELIN ovarian 200 (A vs doxorubicin), 2021 1 0% 364 NA not evaluable Blood creatinine increased TRAE (grade 3-4)detailed results JAVELIN ovarian 200 (A vs doxorubicin), 2021 1.90 [0.06; 56.93]
1.90 [0.06 ; 56.93 ] JAVELIN ovarian 200 (A vs doxorubicin), 2021 1 0% 364 NA not evaluable Colitis TRAE (grade 3-4)detailed results JAVELIN ovarian 200 (A vs doxorubicin), 2021 0.95 [0.02; 47.96]
0.95 [0.02 ; 47.96 ] JAVELIN ovarian 200 (A vs doxorubicin), 2021 1 0% 364 NA not evaluable Constipation TRAE (grade 3-4)detailed results JAVELIN ovarian 200 (A vs doxorubicin), 2021 0.95 [0.02; 47.96]
0.95 [0.02 ; 47.96 ] JAVELIN ovarian 200 (A vs doxorubicin), 2021 1 0% 364 NA not evaluable Decreased appetite TRAE (grade 3-4)detailed results JAVELIN ovarian 200 (A vs doxorubicin), 2021 0.95 [0.02; 47.96]
0.95 [0.02 ; 47.96 ] JAVELIN ovarian 200 (A vs doxorubicin), 2021 1 0% 364 NA not evaluable Diarrhoea TRAE (grade 3-4)detailed results JAVELIN ovarian 200 (A vs doxorubicin), 2021 9.70 [0.53; 178.83]
9.70 [0.53 ; 178.83 ] JAVELIN ovarian 200 (A vs doxorubicin), 2021 1 0% 364 NA not evaluable Dry skin TRAE (grade 3-4)detailed results JAVELIN ovarian 200 (A vs doxorubicin), 2021 0.47 [0.02; 14.15]
0.47 [0.02 ; 14.15 ] JAVELIN ovarian 200 (A vs doxorubicin), 2021 1 0% 364 NA not evaluable Dyspnoea TRAE (grade 3-4)detailed results JAVELIN ovarian 200 (A vs doxorubicin), 2021 1.90 [0.06; 56.93]
1.90 [0.06 ; 56.93 ] JAVELIN ovarian 200 (A vs doxorubicin), 2021 1 0% 364 NA not evaluable Fatigue TRAE (grade 3-4)detailed results JAVELIN ovarian 200 (A vs doxorubicin), 2021 0.16 [0.01; 3.13]
0.16 [0.01 ; 3.13 ] JAVELIN ovarian 200 (A vs doxorubicin), 2021 1 0% 364 NA not evaluable Febrile neutropenia TRAE (grade 3-4)detailed results JAVELIN ovarian 200 (A vs doxorubicin), 2021 0.16 [0.01; 3.13]
0.16 [0.01 ; 3.13 ] JAVELIN ovarian 200 (A vs doxorubicin), 2021 1 0% 364 NA not evaluable Hepatitis TRAE (grade 3-4)detailed results JAVELIN ovarian 200 (A vs doxorubicin), 2021 1.90 [0.06; 56.93]
1.90 [0.06 ; 56.93 ] JAVELIN ovarian 200 (A vs doxorubicin), 2021 1 0% 364 NA not evaluable Hypersensitivity TRAE (grade 3-4)detailed results JAVELIN ovarian 200 (A vs doxorubicin), 2021 0.95 [0.02; 47.96]
0.95 [0.02 ; 47.96 ] JAVELIN ovarian 200 (A vs doxorubicin), 2021 1 0% 364 NA not evaluable Hypertension TRAE (grade 3-4)detailed results JAVELIN ovarian 200 (A vs doxorubicin), 2021 3.82 [0.17; 85.21]
3.82 [0.17 ; 85.21 ] JAVELIN ovarian 200 (A vs doxorubicin), 2021 1 0% 364 NA not evaluable Hyperthyroidism TRAE (grade 3-4)detailed results JAVELIN ovarian 200 (A vs doxorubicin), 2021 1.90 [0.06; 56.93]
1.90 [0.06 ; 56.93 ] JAVELIN ovarian 200 (A vs doxorubicin), 2021 1 0% 364 NA not evaluable Increase AST TRAE (grade 3-4)detailed results JAVELIN ovarian 200 (A vs doxorubicin), 2021 3.82 [0.17; 85.21]
3.82 [0.17 ; 85.21 ] JAVELIN ovarian 200 (A vs doxorubicin), 2021 1 0% 364 NA not evaluable Increased ALT TRAE (grade 3-4)detailed results JAVELIN ovarian 200 (A vs doxorubicin), 2021 0.95 [0.02; 47.96]
0.95 [0.02 ; 47.96 ] JAVELIN ovarian 200 (A vs doxorubicin), 2021 1 0% 364 NA not evaluable Increased lipase level TRAE (grade 3-4)detailed results JAVELIN ovarian 200 (A vs doxorubicin), 2021 1.90 [0.06; 56.93]
1.90 [0.06 ; 56.93 ] JAVELIN ovarian 200 (A vs doxorubicin), 2021 1 0% 364 NA not evaluable Infusion-related reactions TRAE (grade 3-4)detailed results JAVELIN ovarian 200 (A vs doxorubicin), 2021 0.47 [0.02; 14.15]
0.47 [0.02 ; 14.15 ] JAVELIN ovarian 200 (A vs doxorubicin), 2021 1 0% 364 NA not evaluable Leucopenia TRAE (grade 3-4)detailed results JAVELIN ovarian 200 (A vs doxorubicin), 2021 0.16 [0.01; 3.13]
0.16 [0.01 ; 3.13 ] JAVELIN ovarian 200 (A vs doxorubicin), 2021 1 0% 364 NA not evaluable Maculopapular rash TRAE (grade 3-4)detailed results JAVELIN ovarian 200 (A vs doxorubicin), 2021 0.47 [0.02; 14.15]
0.47 [0.02 ; 14.15 ] JAVELIN ovarian 200 (A vs doxorubicin), 2021 1 0% 364 NA not evaluable Mucosal inflammation TRAE (grade 3-4)detailed results JAVELIN ovarian 200 (A vs doxorubicin), 2021 0.31 [0.03; 3.03]
0.31 [0.03 ; 3.03 ] JAVELIN ovarian 200 (A vs doxorubicin), 2021 1 0% 364 NA not evaluable Nausea TRAE (grade 3-4)detailed results JAVELIN ovarian 200 (A vs doxorubicin), 2021 0.47 [0.02; 14.15]
0.47 [0.02 ; 14.15 ] JAVELIN ovarian 200 (A vs doxorubicin), 2021 1 0% 364 NA not evaluable Neutropenia TRAE (grade 3-4)detailed results JAVELIN ovarian 200 (A vs doxorubicin), 2021 0.05 [0.00; 0.87]
0.05 [0.00 ; 0.87 ] JAVELIN ovarian 200 (A vs doxorubicin), 2021 1 0% 364 NA not evaluable Palmar-plantar erythrodysaesthesia syndrome TRAE (grade 3-4)detailed results JAVELIN ovarian 200 (A vs doxorubicin), 2021 0.05 [0.00; 0.87]
0.05 [0.00 ; 0.87 ] JAVELIN ovarian 200 (A vs doxorubicin), 2021 1 0% 364 NA not evaluable Pancytopenia TRAE (grade 3-4)detailed results JAVELIN ovarian 200 (A vs doxorubicin), 2021 0.23 [0.01; 5.24]
0.23 [0.01 ; 5.24 ] JAVELIN ovarian 200 (A vs doxorubicin), 2021 1 0% 364 NA not evaluable Peripheral neuropathy TRAE (grade 3-4)detailed results JAVELIN ovarian 200 (A vs doxorubicin), 2021 0.95 [0.02; 47.96]
0.95 [0.02 ; 47.96 ] JAVELIN ovarian 200 (A vs doxorubicin), 2021 1 0% 364 NA not evaluable Peripheral oedema TRAE (grade 3-4)detailed results JAVELIN ovarian 200 (A vs doxorubicin), 2021 0.95 [0.02; 47.96]
0.95 [0.02 ; 47.96 ] JAVELIN ovarian 200 (A vs doxorubicin), 2021 1 0% 364 NA not evaluable Pneumonia TRAE (grade 3-4)detailed results JAVELIN ovarian 200 (A vs doxorubicin), 2021 1.90 [0.06; 56.93]
1.90 [0.06 ; 56.93 ] JAVELIN ovarian 200 (A vs doxorubicin), 2021 1 0% 364 NA not evaluable Pneumonitis TRAE (grade 3-4)detailed results JAVELIN ovarian 200 (A vs doxorubicin), 2021 0.95 [0.06; 15.24]
0.95 [0.06 ; 15.24 ] JAVELIN ovarian 200 (A vs doxorubicin), 2021 1 0% 364 NA not evaluable Pruritic rash TRAE (grade 3-4)detailed results JAVELIN ovarian 200 (A vs doxorubicin), 2021 0.95 [0.02; 47.96]
0.95 [0.02 ; 47.96 ] JAVELIN ovarian 200 (A vs doxorubicin), 2021 1 0% 364 NA not evaluable Pruritus TRAE (grade 3-4)detailed results JAVELIN ovarian 200 (A vs doxorubicin), 2021 0.95 [0.02; 47.96]
0.95 [0.02 ; 47.96 ] JAVELIN ovarian 200 (A vs doxorubicin), 2021 1 0% 364 NA not evaluable Pyrexia TRAE (grade 3-4)detailed results JAVELIN ovarian 200 (A vs doxorubicin), 2021 0.95 [0.02; 47.96]
0.95 [0.02 ; 47.96 ] JAVELIN ovarian 200 (A vs doxorubicin), 2021 1 0% 364 NA not evaluable Rash TRAE (grade 3-4)detailed results JAVELIN ovarian 200 (A vs doxorubicin), 2021 0.16 [0.01; 3.13]
0.16 [0.01 ; 3.13 ] JAVELIN ovarian 200 (A vs doxorubicin), 2021 1 0% 364 NA not evaluable Sepsis TRAE (grade 3-4)detailed results JAVELIN ovarian 200 (A vs doxorubicin), 2021 0.95 [0.02; 47.96]
0.95 [0.02 ; 47.96 ] JAVELIN ovarian 200 (A vs doxorubicin), 2021 1 0% 364 NA not evaluable Skin exfoliation TRAE (grade 3-4)detailed results JAVELIN ovarian 200 (A vs doxorubicin), 2021 0.95 [0.02; 47.96]
0.95 [0.02 ; 47.96 ] JAVELIN ovarian 200 (A vs doxorubicin), 2021 1 0% 364 NA not evaluable Stomatitis TRAE (grade 3-4)detailed results JAVELIN ovarian 200 (A vs doxorubicin), 2021 0.09 [0.01; 1.70]
0.09 [0.01 ; 1.70 ] JAVELIN ovarian 200 (A vs doxorubicin), 2021 1 0% 364 NA not evaluable Thrombocytopenia TRAE (grade 3-4)detailed results JAVELIN ovarian 200 (A vs doxorubicin), 2021 0.47 [0.02; 14.15]
0.47 [0.02 ; 14.15 ] JAVELIN ovarian 200 (A vs doxorubicin), 2021 1 0% 364 NA not evaluable Vomiting TRAE (grade 3-4)detailed results JAVELIN ovarian 200 (A vs doxorubicin), 2021 0.31 [0.03; 3.03]
0.31 [0.03 ; 3.03 ] JAVELIN ovarian 200 (A vs doxorubicin), 2021 1 0% 364 NA not evaluable 0.0 20.0 1.0 relative treatment effect www.metaEvidence.org 2024-10-04 03:47 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1;
studied treatment is better when TE < 1;
pathologies: 251
- treatments: 417